Ronald McKechnie, MD
Interventional Cardiology · Virginia Beach, VANPI 1689640039
Payments from drug & device makers
Across 108 payments — averaging $82.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Corindus Inc.$1K
- Siemens Medical Solutions USA, Inc.$1K
- Boston Scientific$874
- Abiomed$618
- Abbott$238
- plus $1K from 18 others
What the payments were for
- Travel & lodging$3,33538%
- Food & beverage$5,55562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 35 | $3,728 |
| Corindus Inc. | 9 | $1,239 |
| Siemens Medical Solutions USA, Inc. | 12 | $1,108 |
| Boston Scientific | 8 | $874 |
| Abiomed | 9 | $618 |
| Abbott | 3 | $238 |
| Biotronik Inc. | 3 | $222 |
| Boehringer Ingelheim | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $116 |
| ZOLL Circulation Inc | 1 | $113 |
| Philips North America LLC | 2 | $93 |
| Cardiovascular Systems Inc. | 2 | $83 |
| Amgen | 4 | $60 |
| AstraZeneca | 4 | $55 |
| Johnson & Johnson | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Pfizer | 2 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Chiesi USA, Inc. | 1 | $20 |
| Nuwellis, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CorPath GRX$1,107
- SYMPLICITY G3$1,089
- CorPath Imaging System$335
- AVVIGO Guidance System$256
- OPTICROSS$255
- Impella$225
- OPTIS$180
- Artis Q$171
- Artis pheno$171
- GENERAL VASCULAR ACCESS$150
- CoreValve Evolut$140
- JARDIANCE$125
- LifeVest$116
- TherOx DS2 Console$113
- Catheter$113
- Downstream Cartridge$113
- Acticor$112
- Solia$112
- Rivacor$112
- Edora$112
How this compares
$8,890 in reported general payments places this provider in the 60th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 211 | $227,162 |
| EntrestoSacubitril/Valsartan | 75 | $88,456 |
| FarxigaDapagliflozin Propanediol | 27 | $30,470 |
| Repatha SureclickEvolocumab | 26 | $26,253 |
| XareltoRivaroxaban | 12 | $9,406 |
| Ranolazine ErRanolazine | 46 | $5,454 |
| Rosuvastatin Calcium | 213 | $3,484 |
| Carvedilol | 211 | $2,259 |
| Metoprolol Succinate | 166 | $2,196 |
| Atorvastatin Calcium | 216 | $2,072 |
| ClopidogrelClopidogrel Bisulfate | 129 | $1,553 |
| Nebivolol Hcl | 27 | $1,385 |
| Ezetimibe | 65 | $1,267 |
| Losartan Potassium | 123 | $1,267 |
| Amlodipine Besylate | 171 | $1,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $27 | $227,162211 claims |
| NovartisEntresto | $11 | $88,45675 claims |
| AstraZenecaFarxiga | $55 | $30,47027 claims |
| Johnson & JohnsonXarelto | $47 | $9,40612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Virginia Beach
- Deepak TalrejaVirginia Beach$2M
- Michael GenVirginia Beach$222K
- David AdlerVirginia Beach$59K
- Rajiv TayalFredericksburg$2M
- Michael RagostaCharlottesville$1M
- Jason FoerstRoanoke$956K
- Noah JonesFalls Church$907K
- John SaxonCharlottesville$900K
- Wayne BatchelorFalls Church$723K
- Matthew SummersNorfolk$614K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.